Answers are grounded in this paper and cite their sources.
Pilot study finds urinary VEGF-165b-mRNA linked to treatment duration in Fabry disease, suggesting benefits to nephropathy.
Overexpression of urinary VEGF-165b-mRNA (with known renal cyto-protective effects) is a probable response to injury in FD nephropathy. The only variable correlated with the highest urinary expression of VEGF-165b-mRNA was the time of ERT treatment. Probably in patients with longer treatment time there is a decrease in FD damage. A limitation of the present work is the low sample size and cross-sectional design.
No takes yet. Share an insight, caveat, or question.
Jaurretche et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: